Compare Amphastar Pharmaceuticals Inc (AMPH) vs Coupang Inc (CPNG) Price & Performance

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

CPNG trades at $16.19, down 0.25% on the day, with a bearish technical signal and recent earnings misses. Revenue grew to $34.53B in 2025, but net income margin remains thin at 0.6%. The stock is undervalued on a P/S basis at 0.85, yet high P/E and EV/EBITDA ratios reflect profitability challenges. Analyst consensus is strongly bullish with an average price target of $23.38, suggesting significant upside. Recent news highlights recovery from a data breach and expansion in Taiwan, though a $422M fine in South Korea poses regulatory risks.

The outlook hinges on execution in new markets and margin improvement. Upside potential exists if CPNG meets growth targets and reverses recent earnings underperformance, but investors face risks from competitive pressures, regulatory scrutiny, and volatile cash flows. The stock's current discount to analyst targets presents a opportunity, but sustained profitability is key to unlocking value.